Radisys Showcases Connect Open Broadband Portfolio at Broadband World Forum 2021
11.10.2021 09:00:00 EEST | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, today announced its Connect Open Broadband solution showcase in Booth A24 at Broadband World Forum 2021, with the event exhibition taking place October 13-14 in Amsterdam, and the online event occurring October 11-15. Radisys will present live demonstrations that enable broadband service providers to transform their networks, simplify network operations, and be prepared to meet their customers’ changing needs. Radisys will demonstrate triple-play services, including high-speed internet and video streaming over Gigabit-PON (G-PON) and XGS-PON, and its Smart Home portfolio—including the Radisys Reach Smart Home Gateway and customizable mobile application—along with a sampling of available sensors, cameras and other devices that work together as an integrated solution.
Radisys will join other industry thought leaders in sessions exploring broadband innovation:
- Rajesh Chundury, VP of Customers Solutions, will present, “Advance Your FTTx Network with Cloud-Native Containerized Solutions for PON” on October 11 at 10:30am in the virtual session and live in-person October 14 from 2:10pm-2:30pm.
- Chundury will also participate in the Open Networking Foundation’s workshop “Taking opensource to production in broadband network with VOLTHA, a community view” on October 13, 3:00pm-5:00pm. The discussion will also feature experts from Adtran, Deutsche Telekom, Netsia and Türk Telekom.
The Radisys showcase will feature key solutions from its broadband and Smart Home portfolios. The demonstrations will include the Connect Broadband Access Controller (CBAC)-C (Centralized) and CBAC-D (Distributed) deployments using Radisys’ RLT-1600G and RLT-1600X Optical Line Terminals (OLTs) for fiber to the x (FTTX) deployments.
- Radisys’ CBAC software enables service providers to evolve their fiber networks with an open software solution that facilitates faster product innovation cycles, increased automation, and deeper network visibility.
- The Radisys Combo PON OLT features full PON port flexibility and enables broadband providers to leverage G-PON technology while also providing the option to expand their network and rollout XGS-PON deployments using the same OLT hardware at their pace and optimizing their cost model.
- Radisys’ Optical Network Terminals (ONTs) are built with inherent efficiencies and scalability to support data, voice, video and other broadband services for residential and commercial subscribers on fiber networks.
- Radisys’ Smart Home solutions help service providers broaden the utility of their data plans with life-enriching services and features that consumers want, to create new revenue streams and increase average revenue per user.
“Radisys is delivering best-in-class devices and leading software solutions that add value to the broadband ecosystem, elevating broadband service provider offerings and enhancing their data plans,” said Harris Razak, senior vice president of Broadband Access, Radisys. “Broadband World Forum 2021 is an exciting opportunity to showcase our portfolio that enables service providers to expand their fiber networks with world class solutions and leverage an open device ecosystem to create new revenue streams.”
To see the technology demonstrations, or to meet with Radisys’ open telecom experts at Broadband World Forum 2021, contact open@radisys.com.
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.Radisys.com.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211010005025/en/
Contact information
Nereus for Radisys
Lori Mesecke, +1-503-459-9150
lmesecke@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom